Melanoma: Surgery Subsequent to PDT—Is It Worth Doing? A 10-Year Pilot Trial Using Chlorin-Type Photosensitizer Bremachlorin<sup>®</sup>
- 1 State Budget Healthcare Facility “Sverdlovskiy Oblastnoy Oncologicheskiy Dispancer”, Ekaterinburg, Russia
- 2 AREV PHARM LLC., Moscow, Russia
- 3 RADA-PHARMA International B.V., Steenbergen, The Netherlands
Abstract
Bremachlorin ® , also known as “Radachlorin ® ” and Photochlorin, a composition of 3 chlorophyll a derivatives in an aqueous solution [1] , was initially introduced into the Russian and South Korean Pharmacopoeias with the corresponding marketing authorizations received in 2006 and 2008, on the basal cell skin carcinoma PDT protocol. Phase I-II clinical trials led in 2002-2005 showed no side effects, a good tolerability by patients and a high clinical anti-tumor efficacy. Further studies described in the present paper were fulfilled in accordance with a skin melanoma PDT + surgery combined technique protocol in 2006-2016. Resulting from the present trial, up to the 100% complete responses were achieved after resection and plastic surgery following PDT, with no melanoma regrowth or metastases during 5 and 10-year observation periods. Conducting PDT one day prior to tumor dissection can guarantee to meet the ablastics principles at the subsequent surgery. At the same time, the PDT + surgery protocol can allow for dissecting the tumor with less distance from its edge, which seems to be important for the face localizations of tumors.
- Reshetnickov, A.V., et al. (2001) Photosensitizer, and Method Therefore. Patents of South Africa-2003/8407, Australia-2002212867, New Zealand-528237, United Kingdom-GB2389531, Norway-327751, Sweden-01981209.8, Italy-70446-BE/2009, Slovenia, The Netherlands, Rep. of Ireland, France, Germany, Switzerland, Belgium-1380295. Assignee: RADA-PHARMA International B.V., The Netherlands, Priority of 04.10.2001.
- Cohen, D.K. and Lee, P.K. (2016) Photodynamic Therapy for Non-Melanoma Skin Cancers. Cancers, 8, 90. https://doi.org/10.3390/cancers8100090
- Voet, M.A. (2004) Photodynamic Therapy for Pre-Melanomas. US Pat.6,723,750. Assignee: Allergan Inc., Irvine, CA, Priority of 20.04.2004.
- Kochneva, E.V., Filonenko, E.V., Vakulovskaya, E.G., Scherbakova, E.G., Seliverstov, O.V., Markichev, N.A. and Reshetnickov, A.V. (2010) Photosensitizer Radachlorin®: Skin Cancer PDT Phase II Clinical Trials. Photodiagnosis and Photodynamic Therapy, 7, 258-267. https://doi.org/10.1016/j.pdpdt.2010.07.006
- Reshetnickov, A.V. and Mead, M.N. (2013) The Medicine of Light. The 1st Edition, Amazon Press, USA, 255 p. (2014) The 2nd Edition, Pumbo, The Netherlands, 271 p. © by Photoimmune Discoveries B.V. http://www.photoimmune.org/
- Douillard, S, Olivier, D, Patrice, T. (2009) In Vitro and In Vivo Evaluation of Radachlorin Sensitizer for Photodynamic Therapy. Photochemical & Photobiological Sciences, 8, 405-413. https://doi.org/10.1039/b817175k
- Markichev, N.A., Eliseyenko, V.I., Alexeyev, Y.V., Armichev, A.V. and Reshetnickov, A.V. (2004) Photodynamic Therapy of Cutaneous Basal-Cell Carcinoma Using Photosensitizer from the Chlorins Family Radachlorin. Laser Medicine, 8, 144-145. (in Russian)
- Peris, K., Tambone, S., Kostaki, D., Varrassi, E. and Fargnoli, M.C. (2014) Treatments of Advanced Basal Cell Carcinoma: A Review of the Literature. Giornale Italiano Di Dermatologia E Venereologia, 151, 77-86.
- Ahn, J.C., Biswas, R., Mondal, A., Lee, Y.K. and Chung, P.S. (2013) Cisplatin Enhances the Efficacy of 5-Aminolevulinic Acid Mediated Photodynamic Therapy in Human Head and Neck Squamous Cell Carcinoma. General Physiology and Biophysics, 33, 53-62. https://doi.org/10.4149/gpb_2013046
- Paches, A.I. (2000) Head and Neck Tumors. Moscow, Russia (in Russian).
- Demidov, L.V., Kharkevich, G.Yu. (2003) Skin Melanoma: Staging, Diagnostics and Treatment. The Russian Medical Journal, 11, 41-43. (in Russian).